Vision for Europe:
Innovation, Investment, Excellence
The European Union continues to grow as a region of healthcare biotech excellence. Creating an environment to attract, maintain, and grow investments in innovative healthcare biotech discoveries will ensure that the EU is the world’s most advanced region for both public and private biotech research and development.
EuropaBio’s vision: A Europe where biotechnology delivers benefits across society, from high-skill jobs and economic strength to ground-breaking treatments that change and save lives.
We are joining forces with innovators, policy-makers and other key actors in biotechnology to deliver on this vision for Europe.
Together, we will revolutionise the future of healthcare.
Browse our knowledge hub – featuring EuropaBio and member reports, white papers, case studies, publications, consultation responses and infographics that provide insight on a range of topics related to healthcare innovation, investment and excellence in Europe.
Europe has the potential to become the world’s most innovative biotech region by creating the right environment to attract investments and excellence
The EU needs to make sure that our single market works for innovation.
New medicines don’t fall from trees – they require the right eco-system and careful nurturing! Europe is the richest continent in the world with the highest skills level and the best innovators. Let’s live up to that reality when it comes to protecting and promoting innovation!
Research and development is not an engine you can simply turn off and on.
It's an interdependent ecosystem requiring nurture and care in order to create the right environment for innovation to flourish. In order to serve the patient’s needs, the EU needs a strong Intellectual Property framework to recognise the significant investments in the treatments of tomorrow.
The EU has the potential to become the world’s most innovative biotech region.
With that in mind EuropaBio welcomes the EC’s intention of supporting “a competitive and innovative European pharmaceutical environment” (as stated in the EC’s 2020 Pharmaceutical Strategy for Europe). To realise this goal the EU must address the factors that are causing Europe to fall behind, such as creating a world class regulatory framework and an environment that incentivises and rewards innovation. A successful pharmaceutical sector in the EU not only has the prospect of improving public health and saving lives but can also create jobs and wealth for our economy.
The EU needs to continue to strengthen opportunities.
The EU has the potential to become the world’s most innovative biotech region by creating the right environment to attract investments and excellence. To do so, the EU needs to continue to strengthen opportunities for meaningful patient-centric, value-based partnerships. By leveraging shared innovation, ideas and investments, we (the pharma industry) can drive greater impact for patients across the region.